<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04765137</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00256402</org_study_id>
    <nct_id>NCT04765137</nct_id>
  </id_info>
  <brief_title>Evaluate the Effect of Atorvastatin on Cerebrovascular Reactivity in MCI</brief_title>
  <official_title>Targeting Cerebrovascular Reactivity for Precision Medicine: Pilot Trial of Atorvastatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of atorvastatin on brain vessel&#xD;
      reactivity and with it on blood flow in people with mild cognitive impairment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants are first being informed about potential benefits and risks of the study and are&#xD;
      required to give written consent. After that participants will undergo detailed phone screen&#xD;
      to determine eligibility for study entry. At week 0, participants who meet eligibility&#xD;
      requirements will be prescribed atorvastatin (40 mg, once in the evening) in an open-label&#xD;
      manner.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2021</start_date>
  <completion_date type="Anticipated">June 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-label study with atorvastatin 40 mg</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of MRI whole brain cerebrovascular reactivity (wbCVR)</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>MRI based CVR is a newer technique that measures dilatory function of the microvessels which have been shown to be superior to measurement of Cerebral blood flow (CBF) and have also been shown to be low in participants with MCI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in plasma exosomes</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Endothelial-derived exosomes (EDE) reflect the neurochemistry of cerebrovascular endothelial cells, while neuronal-enriched extracellular vesicles (nEV) are associated with brain white matter hyperintensities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cognitive function (global neurocognitive measure)</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Assessed by Global neurocognitive measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cognitive function (domain-specific neurocognitive measure)</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Assessed by Domain-specific neurocognitive measure.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Atorvastatin 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive 40 mg atorvastatin orally daily in the evening.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin Oral Tablet</intervention_name>
    <description>Atorvastatin pill 40 mg to be taken every night</description>
    <arm_group_label>Atorvastatin 40 mg</arm_group_label>
    <other_name>Lipitor oral tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria are chosen to include participants with MCI, enriched for vascular risk&#xD;
        factors:&#xD;
&#xD;
          -  MCI defined by CDR of 0.5 or 1.0.&#xD;
&#xD;
          -  Memory, processing speed, executive function, language - cognitive scores &gt; 1.5&#xD;
             standard deviations below age-education norms.&#xD;
&#xD;
          -  Not demented by history.&#xD;
&#xD;
          -  Not taking statins currently or in the last 6 months.&#xD;
&#xD;
          -  Cognitive/functional impairment not likely due to another neurological disease or&#xD;
             delirium.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Taking a statin currently or have taken a statin in the last 6 months.&#xD;
&#xD;
          -  Contraindications to taking a statin.&#xD;
&#xD;
          -  Transplant patient taking cyclosporine.&#xD;
&#xD;
          -  Unable to undergo MRI procedures (such as having an implanted pacemaker or&#xD;
             defibrillator or stimulator or having non MRI compatible metal).&#xD;
&#xD;
          -  Diagnosis of dementia by history.&#xD;
&#xD;
          -  Current diagnosis of substance abuse.&#xD;
&#xD;
          -  History of stroke or myocardial infarction in past 6 months.&#xD;
&#xD;
          -  History of HIV.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sevil Yasar, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samantha Horn</last_name>
    <phone>410-550-9020</phone>
    <email>shorn8@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ritu Agarwal</last_name>
    <phone>410-550-9020</phone>
    <email>ragarw19@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Johns Hopkins University, Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Horn</last_name>
      <phone>410-550-9020</phone>
      <email>shorn8@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ritu Agarwal</last_name>
      <phone>410-550-9020</phone>
      <email>ragarw19@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Sevil Yasar, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Rosenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 18, 2021</study_first_submitted>
  <study_first_submitted_qc>February 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>May 28, 2021</last_update_submitted>
  <last_update_submitted_qc>May 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cerebral Vascular Reactivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

